MANNKIND CORP (MNKD) Fundamental Analysis & Valuation

NASDAQ:MNKD • US56400P7069

Current stock price

2.57 USD
+0.01 (+0.39%)
At close:
2.57 USD
0 (0%)
After Hours:

This MNKD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. MNKD Profitability Analysis

1.1 Basic Checks

  • MNKD had positive earnings in the past year.
  • MNKD had a positive operating cash flow in the past year.
  • In multiple years MNKD reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: MNKD reported negative operating cash flow in multiple years.
MNKD Yearly Net Income VS EBIT VS OCF VS FCFMNKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

  • The Return On Assets of MNKD (0.85%) is better than 87.81% of its industry peers.
  • MNKD has a better Return On Invested Capital (7.96%) than 91.88% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for MNKD is significantly below the industry average of 27.63%.
Industry RankSector Rank
ROA 0.85%
ROE N/A
ROIC 7.96%
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
MNKD Yearly ROA, ROE, ROICMNKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100 -150

1.3 Margins

  • The Profit Margin of MNKD (1.92%) is better than 88.20% of its industry peers.
  • Looking at the Operating Margin, with a value of 16.59%, MNKD belongs to the top of the industry, outperforming 92.65% of the companies in the same industry.
  • The Gross Margin of MNKD (77.80%) is better than 84.14% of its industry peers.
  • MNKD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 16.59%
PM (TTM) 1.92%
GM 77.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
MNKD Yearly Profit, Operating, Gross MarginsMNKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

3

2. MNKD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MNKD is creating some value.
  • The number of shares outstanding for MNKD has been increased compared to 1 year ago.
  • MNKD has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MNKD is higher compared to a year ago.
MNKD Yearly Shares OutstandingMNKD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
MNKD Yearly Total Debt VS Total AssetsMNKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • MNKD has an Altman-Z score of -4.22. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
  • MNKD has a Altman-Z score of -4.22. This is comparable to the rest of the industry: MNKD outperforms 40.23% of its industry peers.
  • MNKD has a debt to FCF ratio of 44.51. This is a negative value and a sign of low solvency as MNKD would need 44.51 years to pay back of all of its debts.
  • MNKD's Debt to FCF ratio of 44.51 is amongst the best of the industry. MNKD outperforms 88.78% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.51
Altman-Z -4.22
ROIC/WACC0.93
WACC8.52%
MNKD Yearly LT Debt VS Equity VS FCFMNKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 1.70 indicates that MNKD should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.70, MNKD is doing worse than 79.88% of the companies in the same industry.
  • A Quick Ratio of 1.50 indicates that MNKD should not have too much problems paying its short term obligations.
  • MNKD has a worse Quick ratio (1.50) than 80.85% of its industry peers.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.5
MNKD Yearly Current Assets VS Current LiabilitesMNKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

6

3. MNKD Growth Analysis

3.1 Past

  • MNKD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.75%.
  • The Revenue has grown by 22.23% in the past year. This is a very strong growth!
  • MNKD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 39.91% yearly.
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%

3.2 Future

  • The Earnings Per Share is expected to grow by 52.44% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, MNKD will show a quite strong growth in Revenue. The Revenue will grow by 17.70% on average per year.
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue Next Year36.86%
Revenue Next 2Y23.74%
Revenue Next 3Y16.07%
Revenue Next 5Y17.7%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MNKD Yearly Revenue VS EstimatesMNKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
MNKD Yearly EPS VS EstimatesMNKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 -1 -1.5

5

4. MNKD Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 42.83, MNKD can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, MNKD is valued cheaper than 90.72% of the companies in the same industry.
  • MNKD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.78.
  • The Price/Forward Earnings ratio is 48.25, which means the current valuation is very expensive for MNKD.
  • MNKD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MNKD is cheaper than 89.75% of the companies in the same industry.
  • MNKD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.54.
Industry RankSector Rank
PE 42.83
Fwd PE 48.25
MNKD Price Earnings VS Forward Price EarningsMNKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 94.00% of the companies in the same industry are more expensive than MNKD, based on the Enterprise Value to EBITDA ratio.
  • 92.65% of the companies in the same industry are more expensive than MNKD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 57.84
EV/EBITDA 15.59
MNKD Per share dataMNKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • The decent profitability rating of MNKD may justify a higher PE ratio.
  • A more expensive valuation may be justified as MNKD's earnings are expected to grow with 65.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y91.27%
EPS Next 3Y65.59%

0

5. MNKD Dividend Analysis

5.1 Amount

  • No dividends for MNKD!.
Industry RankSector Rank
Dividend Yield 0%

MNKD Fundamentals: All Metrics, Ratios and Statistics

MANNKIND CORP

NASDAQ:MNKD (4/10/2026, 6:43:57 PM)

After market: 2.57 0 (0%)

2.57

+0.01 (+0.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners58.06%
Inst Owner Change0%
Ins Owners1.57%
Ins Owner Change2.58%
Market Cap791.82M
Revenue(TTM)348.97M
Net Income(TTM)6.70M
Analysts84
Price Target7.65 (197.67%)
Short Float %7.61%
Short Ratio3.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-116.48%
Min EPS beat(2)-439.47%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)-85.96%
Min EPS beat(4)-439.47%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-74.12%
EPS beat(12)5
Avg EPS beat(12)-38.6%
EPS beat(16)6
Avg EPS beat(16)-28.6%
Revenue beat(2)2
Avg Revenue beat(2)6.39%
Min Revenue beat(2)0.33%
Max Revenue beat(2)12.45%
Revenue beat(4)3
Avg Revenue beat(4)2.28%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)12.45%
Revenue beat(8)6
Avg Revenue beat(8)2.33%
Revenue beat(12)9
Avg Revenue beat(12)3.51%
Revenue beat(16)12
Avg Revenue beat(16)6.12%
PT rev (1m)-21.97%
PT rev (3m)-17.18%
EPS NQ rev (1m)-164.32%
EPS NQ rev (3m)-142.9%
EPS NY rev (1m)0%
EPS NY rev (3m)-51.42%
Revenue NQ rev (1m)-1.26%
Revenue NQ rev (3m)5.83%
Revenue NY rev (1m)1.8%
Revenue NY rev (3m)11.75%
Valuation
Industry RankSector Rank
PE 42.83
Fwd PE 48.25
P/S 2.27
P/FCF 57.84
P/OCF 43.38
P/B N/A
P/tB N/A
EV/EBITDA 15.59
EPS(TTM)0.06
EY2.33%
EPS(NY)0.05
Fwd EY2.07%
FCF(TTM)0.04
FCFY1.73%
OCF(TTM)0.06
OCFY2.31%
SpS1.13
BVpS-0.17
TBVpS-1.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.85%
ROE N/A
ROCE 9.32%
ROIC 7.96%
ROICexc 10.76%
ROICexgc 55.79%
OM 16.59%
PM (TTM) 1.92%
GM 77.8%
FCFM 3.92%
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
ROICexc(3y)28.62%
ROICexc(5y)N/A
ROICexgc(3y)44.91%
ROICexgc(5y)N/A
ROCE(3y)12.18%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.51
Debt/EBITDA 8.33
Cap/Depr 37.17%
Cap/Sales 1.31%
Interest Coverage 3.93
Cash Conversion 26.02%
Profit Quality 204.41%
Current Ratio 1.7
Quick Ratio 1.5
Altman-Z -4.22
F-Score5
WACC8.52%
ROIC/WACC0.93
Cap/Depr(3y)368.18%
Cap/Depr(5y)300.07%
Cap/Sales(3y)8.68%
Cap/Sales(5y)9.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%
Revenue Next Year36.86%
Revenue Next 2Y23.74%
Revenue Next 3Y16.07%
Revenue Next 5Y17.7%
EBIT growth 1Y-18.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.06%
OCF growth 3YN/A
OCF growth 5YN/A

MANNKIND CORP / MNKD Fundamental Analysis FAQ

What is the fundamental rating for MNKD stock?

ChartMill assigns a fundamental rating of 5 / 10 to MNKD.


Can you provide the valuation status for MANNKIND CORP?

ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.


What is the profitability of MNKD stock?

MANNKIND CORP (MNKD) has a profitability rating of 6 / 10.


How financially healthy is MANNKIND CORP?

The financial health rating of MANNKIND CORP (MNKD) is 3 / 10.


Can you provide the expected EPS growth for MNKD stock?

The Earnings per Share (EPS) of MANNKIND CORP (MNKD) is expected to decline by -6.55% in the next year.